An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee
Latest Information Update: 13 May 2024
At a glance
- Drugs Humantakinogene hadenovec (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Flexion Therapeutics; Pacira BioSciences
- 07 May 2024 According to a Pacira BioSciences media release, positive efficacy and safety data from this study was presented at the Osteoarthritis Research Society International, or OARSI, 2024 World Congress in Vienna, Austria.
- 07 May 2024 According to a Pacira BioSciences media release, company expects to submit updated data demonstrating PCRX-201's effectiveness through two years for presentation at a medical meeting in the Fall.
- 13 Mar 2024 According to a Flexion Therapeutics media release, the 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.